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revealed the burden of ineffectively controlled 
symptoms such as chronic breathlessness, depres‑
sion, and anxiety among patients with end ‑stage 
COPD.1-3 Compared with other life ‑limiting con‑
ditions, these patients experience lower quality 
of life, and yet they have limited access to PC or 
INTRODUCTION A steadily rising number of pa‑
tients diagnosed with chronic obstructive pulmo‑
nary disease (COPD), especially those at an ad‑
vanced stage of the disease, has triggered an on‑
going debate over palliative care (PC) for this 
particular group of patients. Numerous studies 
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INTRODUCTION There is evidence that people with nonmalignant disease receive poorer end ‑of ‑life (EOL) 
care compared with people with cancer.
OBJECTIVES The aim of the study was to assess the selected aspects of symptomatic treatment and 
communication between physicians and patients diagnosed with either advanced chronic obstructive 
pulmonary disease (COPD) or lung cancer.
METHODS A questionnaire survey was conducted online among members of the Polish Respiratory Society.
RESULTS Properly completed questionnaires were returned by 174 respondents (27.2% of those 
proved to be contacted by email). In COPD, 32% of respondents always or often used opioids in chronic 
breathlessness and 18.3% always or often referred patients to a palliative care (PC) specialist. Nearly 
80% of the respondents claimed that bedside discussions on EOL issues with people with COPD are 
essential, although only 20% would always or often initiate them. In people with lung cancer, opioids 
were routinely used for relief of chronic breathlessness by 80% of physicians; 81.7% referred patients 
to a PC specialist. More than half of the respondents always or often discussed EOL issues only with 
the patient’s caregivers or relatives. Younger physicians, those at an earlier stage of their career, those 
caring for higher numbers of patients with lung cancer, and those who were better acquainted with 
Polish Respiratory Society recommendations for PC in chronic lung diseases seemed to provide better 
EOL care for COPD patients.
CONCLUSIONS Patients with COPD, as compared with patients with lung cancer, were less frequently 
treated with opioids to relieve chronic breathlessness or referred for a PC consultation. Discussing 
the EOL issues with a patient was generally found challenging by physicians, and most often pursued 
with caregivers instead. The COPD recommendations on PC may prove helpful in providing better EOL 
care by pulmonologists.
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recommendations in everyday clinical practice. 
We aimed to compare how attending pulmonary 
physicians treated symptoms and communicat‑
ed with patients with advanced COPD and those 
with lung cancer. The comparison between COPD 
and lung cancer seems to be relevant since both 
conditions are characterized by common patho‑
genesis,17 similar presentation, and comparable 
prognosis at their advanced stage.
METHODS The online questionnaire was de‑
veloped for the purpose of this research, based 
on a tool used in a Portuguese study by Gaspar 
et al,18 but expanded to 2 patient populations, 
namely, those with advanced COPD and those 
with lung cancer. The questionnaire was divid‑
ed into 5 thematic domains: symptom manage‑
ment, EOL communication, participants in EOL 
communication, obstacles to EOL communica‑
tion, and a sense of dignity in a COPD patient.
With regard to the first 3 domains, a Likert 
scale was used to elicit respondents’ opinions 
(1 – never; 2 – seldom; 3 – occasionally; 4 – often; 
and 5 – always). In the “obstacles to communica‑
tion” category, respondents were asked to mark 
as many options as they deemed essential. Final‑
ly, there was an open question on how to support 
dignity in a patient with COPD at the end of life.
The questionnaire was loaded onto the Survio 
survey platform (https://www.survio.com). All 
members of the PRS who were also physicians 
were sent an email with an invitation to complete 
the questionnaire anonymously, and a reminder 
was sent 3 times within 4 months.
The study protocol was approved by the Bio‑
ethics Review Committee at Nicolaus Copernicus 
University in Toruń, Collegium Medicum in Byd‑
goszcz, Poland (Ref. No. KB 667/2016).
Statistical analysis The differences in the re‑
sults between people with COPD and lung can‑
cer measured on the ordinal scale were tested us‑
ing the Mann–Whitney test. Nominal variables 
were assessed with the χ2 independence test. 
Correlations between the variables were estab‑
lished with the Kendall’s τ ‑b correlation coeffi‑
cient. The level of statistical significance was set 
at a P value of less than 0.01. The SPSS software 
(IBM SPSS Statistics 24.0.0; SPSS Inc., Armonk, 
New York, United States) was used for analyses.
RESULTS Study participants An invitation to 
participate in the study was sent to 958 email ad‑
dresses from the database of the PRS; however, 
only 639 respondents were contactable by e mail 
(Supplementary material, Figure S1). A total of 
176 members of the PRS completed the survey; 
however, 2 questionnaires were excluded from 
the analysis due to critical technical errors. Fi‑
nally, 174 correctly completed questionnaires 
were received, yielding a response rate of 27.2% 
(174 of 639). The average age of respondents was 
49 years (range, 28–86 years; TABLE 1) and 59% of 
respondents were women. Most people worked 
even a PC consultation.4-6 There is also evidence 
of ineffective communication between pulmo‑
nologists and people with COPD, especially on 
end ‑of ‑life (EOL) issues.7-9 Patients usually ex‑
pect their physicians to be able to explain to them 
the key aspects of their condition, including fu‑
ture care needs. On the other hand, patients usu‑
ally do not initiate conversations about EOL is‑
sues themselves during a consultation.10,11 Re‑
cently, international and local recommendations 
for PC in advanced nonmalignant lung diseases 
have been introduced, including guidelines of 
the Polish Respiratory Society (PRS).12-16
We carried out a questionnaire survey among 
Polish pulmonologists 5 years after the publica‑
tion of the Polish guidelines, with the aim to as‑
sess their understanding and uptake of specific 
TABLE 1 Participants’ characteristics
Age, mean (SD) 49.2 (11)
Female sex 102 (58.6)
Years of practice <5 years 6 (3)
5–9 years 9 (5)
10–19 years 48 (28)
20–29 years 66 (38)
>30 years 45 (26)
Specialty held Respiratory medicine 156 (90)
Allergology 21 (12)
Palliative medicine 5 (3)
The main place of work University hospital 50 (29)
Another hospital 75 (43)
Outpatient clinic 32 (18)
Private practice 10 (6)
Number of COPD patients 




Number of lung cancer 





Number of category D 
patients with COPD 




Knowledge of PRS 
guidelines on PC in lung 
diseases
I know them and I have read them. 70 (40.2)
I have heard about them and looked 
through them briefly.
63 (36.2)
I have heard about them, but not 
read them.
18 (10.3)
I have never heard of them. 23 (13.2)





I prefer not to answer. 15 (8.6)
Data are presented as number (percentage) unless otherwise indicated.
Abbreviations: COPD, chronic obstructive pulmonary disease; PC, palliative care; PRS, 
Polish Respiratory Society
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patients with advanced lung cancer than in those 
with COPD (always or often, 86.8% and 28.2%, 
respectively; TABLE 2). As to relieving chronic 
breathlessness20 in people with advanced lung 
cancer, opioids were used significantly more of‑
ten than in advanced COPD (always or often, 
79.4% and 32.2%, respectively). For people with 
COPD, the majority of physicians used opioids 
only occasionally (31.6%), or seldom or never 
(36%; TABLE 2).
The majority of study participants who used 
opioids to relieve chronic breathlessness in pa‑
tients with COPD often or always noticed ben‑
efits (65.5%). More physicians never had any 
concerns that would made them reluctant to use 
opioids in chronic breathlessness while treating 
patients with lung cancer as compared with pa‑
tients with COPD (62% and 17.8%, respectively).
Among 96 answers (given by 82 participants) 
to the open question about the fears connected 
in the profession for over 10 years, and near‑
ly 90% of respondents held a specialization in 
pulmonology. For 29% of respondents, the main 
place of work was a university hospital, and for 
43%, another type of hospital. The majority of 
respondents (88%) treated more than 50 peo‑
ple with COPD within a year, with 70% caring 
for 30 or more people with category D accord‑
ing to the Global Initiative for Chronic Obstruc‑
tive Lung Disease classification in the preceding 
year.19 More than half of respondents (56%) cared 
for at least 50 people with lung cancer within a 
year. Most of the pulmonologists who partici‑
pated in the study were aware of the PRS guide‑
lines on PC in chronic lung diseases: 40% of re‑
spondents had read them and 36% briefly re‑
viewed them.
Relief of symptoms As to relieving moderate or 
severe pain, opioids were more often used in 
TABLE 2 Relieving the symptoms in people with advanced lung cancer or advanced chronic obstructive pulmonary 
disease
Lung cancer COPD P value z score
Frequency of opioid use in relieving 
severe to moderate pain in patients 
with advanced stages of the disease
1 – never 7 (4) 33 (19) <0.001 –11.69
2 – seldom 0 33 (19)
3 – occasionally 16 (9.2) 59 (33.9)
4 – often 63 (36.2) 41 (23.6)
5 – always 88 (50.6) 8 (4.6)
Median 5 3
Frequency of opioid use in relieving 
chronic breathlessness in patients 
with advanced stages of the disease
1 – never 9 (5.2) 29 (16.7) <0.001 –9.11
2 – seldom 9 (5.2) 34 (19.5)
3 – occasionally 18 (10.3) 55 (31.6)
4 – often 69 (39.7) 44 (25.3)
5 – always 69 (39.7) 12 (6.9)
Median 4 3
Frequency of concerns regarding 
opioid use in patients with chronic 
breathlessness in advanced stages of 
the disease
1 – never 102 (62) 31 (17.8) <0.001 –9.27
2 – seldom 47 (27) 60 (34.5)
3 – occasionally 14 (8) 43 (24.7)
4 – often 4 (2.3) 28 (16.1)
5 – always 1 (0.6) 12 (6.9)
Median 1 2
Frequency of favorable effects of opioid 
use in COPD patients with chronic 
breathlessness
1 – never – 12 (6.9) – –
2 – seldom – 11 (6.3)
3 – occasionally – 37 (21.3)
4 – often – 95 (54.6)
5 – always – 19 (10.9)
Median – 4
Frequency of recommending 
antidepressant or anxiolytic therapy in 
patients with depression or anxiety 
disorders in advanced stages of 
the disease
1 – never 1 (0.6) 1 (0.6) NS –1.67
2 – seldom 16 (9.2) 27 (15.5)
3 – occasionally 59 (33.9) 58 (33.3)
4 – often 74 (42.5) 72 (41.4)
5 – always 24 (13.8) 16 (9.2)
Median 4 4
Data are presented as number (percentage) unless otherwise stated.
Abbreviations: NS, nonsignificant; others, see TABLE 1
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COPD. Younger pulmonologists, those earlier in 
their career, and those with a better knowledge 
of the PRS guidelines were also more open to see 
favorable effects of opioids in patients with COPD 
and chronic breathlessness. A significant relation‑
ship was revealed between the frequency of con‑
cerns about the use of opioids in patients with 
COPD and lower familiarity with the PRS guide‑
lines for PC in lung disease.
No significant difference was observed in 
the pulmonologists’ attitude to the treatment 
of mood disorders in patients with COPD and lung 
cancer (TABLE 2). Prescribing antidepressants and 
anxiolytics in both groups of patients was corre‑
lated with the number of people with lung cancer 
treated within a year (TABLE 3). A significant rela‑
tionship was also revealed between the frequency 
of recommending antidepressants and anxiolyt‑
ics in patients with lung cancer and good knowl‑
edge of the PRS guidelines.
End -of -life communication Most of the respon‑
dents believed that discussions about the EOL 
issues with patients with COPD were essential 
(79%; TABLE 4), yet only 20% of respondents often 
or always initiated these conversations. Slightly 
with using opioids, the majority were related to 
the risk of respiratory depression (n = 56) and 
the balance with adverse effects such as constipa‑
tion, nausea, or drowsiness (n = 12), and the po‑
tential for serious complications such as con‑
sciousness disturbances (n = 6) or development 
of opioid addiction (n = 4).
The correlation analysis revealed a significant 
relationship between the frequency of using opi‑
oids to relieve pain and chronic breathlessness 
and the following factors: age, work experience, 
number of people with lung cancer treated with‑
in a year, and knowledge of the PRS guidelines 
for PC in lung diseases (TABLE 3).
Study participants who had better knowledge 
of the PRS guidelines were more likely to use opi‑
oids for pain and chronic breathlessness in both 
groups of patients. Younger respondents and 
those treating higher numbers of patients with 
lung cancer were more open to the use of opi‑
oids to manage pain in people with COPD and 
to reduce chronic breathlessness in both patient 
groups.
Study participants who were at earlier stages 
of their career were more likely to use opioids for 
pain and chronic breathlessness in people with 
TABLE 3 Relationship between the variables and the frequency of opioid use, depression or anxiety treatment, favorable effects of opioids, and 
concerns regarding opioid use
Variables Test Frequency of opioid 
use in relieving 
severe or moderate 
pain
Frequency of opioid 



























Agea Coefficient –0.12 –0.24 –0.17 –0.21 –0.04 –0.08 –0.21 0.13 0.10
Significance NS <0.001 0.005 <0.001 NS NS <0.001 NS NS
Sexb Test value –0.35 –1.29 –0.19 –0.17 –0.58 –0.60 –1.06 –0.69 –1.46
Significance NS NS NS NS NS NS NS NS NS
Work 
experiencea
Coefficient –0.09 –0.22 –0.14 –0.21 –0.03 –0.09 –0.23 0.13 0.12






Coefficient  – 0.02 –0.02 –0.06 –0.01 0.01 0.08 0.04 0.07 –0.03
Significance NS NS NS NS NS NS NS NS NS





Coefficient 0.10 0.22 0.22 0.21 0.26 0.28 0.14 –0.02 –0.03




Coefficient –0.20 –0.22 –0.21 –0.23 –0.20 –0.17 –0.18 0.01 0.17





Value of test –0.97 –1.15 –0.94 –0.31 –0.78 –0.33 –0.61 –0.53 –0.24
Significance NS NS NS NS NS NS NS NS NS
a The Kendall’s τ ‑b correlation coefficient was applied.
b The Mann–Whitney test was applied.
Abbreviations: see TABLES 1 and 2
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TABLE 4 End ‑of ‑life communication with people with advanced chronic obstructive pulmonary disease or advanced lung cancer (continued on the 
next page)
Lung cancer COPD P value z score
Frequency of initiating a talk 
with patients regarding EOL 
issues
1 – never 22 (12.6) 26 (14.9) 0.001 –3.40
2 – seldom 42 (24.1) 64 (36.8)
3 – occasionally 42 (24.1) 49 (28.2)
4 – often 49 (28.2) 27 (15.5)
5 – always 19 (10.9) 8 (4.6)
Median 3 2
Frequency of talks with patients on the subject of:
Disease progression 1 – never 0 0 NS –1.92
2 – seldom 15 (8.6) 10 (5.7)
3 – occasionally 39 (22.4) 25 (13.2)
4 – often 74 (42.5) 89 (51.1)
5 – always 46 (26.4) 52 (29.9)
Median 4 4
Everyday needs 1 – never 1 (0.6) 3 (1.7) NS –0.31
2 – seldom 22 (12.6) 18 (10.3)
3 – occasionally 44 (25.3) 42 (24.1)
4 – often 63 (36.2) 77 (44.3)
5 – always 44 (25.3) 34 (19.5)
Median 4 4
End ‑of ‑life symptoms 1 – never 18 (10.3) 24 (13.8) 0.004 –2.90
2 – seldom 43 (24.7) 57 (32.8)
3 – occasionally 45 (25.9) 52 (29.9)
4 – often 49 (28.2) 31 (17.8)
5 – always 19 (10.9) 10 (5.7)
Median 3 3
Religious/spiritual needs 1 – never 42 (24.1) 50 (28.7) NS –2.23
2 – seldom 50 (28.7) 64 (36.8)
3 – occasionally 38 (21.8) 32 (18.4)
4 – often 29 (16.7) 20 (11.5)
5 – always 15 (8.6) 8 (4.6)
Median 2 2
Frequency of making a suggestion to the patient that a decision needs to be made on:
Invasive mechanical ventilation 1 – never 75 (43.1) 21 (12.1) <0.001 –7.13
2 – seldom 47 (27) 37 (21.3)
3 – occasionally 26 (14.9) 54 (31)
4 – often 19 (10.9) 50 (28.7)
5 – always 7 (4) 12 (6.9)
Median 2 3
Cardiopulmonary resuscitation 1 – never 85 (48.9) 42 (24.1) <0.001 –4.77
2 – seldom 53 (30.5) 59 (33.9)
3 – occasionally 17 (9.8) 51 (29.3)
4 – often 12 (6.9) 19 (10.9)
5 – always 7 (4) 3 (1.7)
Median 2 2
Place of dying 1 – never 42 (24.1) 65 (37.4) <0.001 –3.87
2 – seldom 46 (26.4) 56 (32.2)
3 – occasionally 38 (21.8) 30 (17.2)
4 – often 34 (19.5) 18 (10.3)
5 – always 14 (8) 5 (2.9)
Median 2 2
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Referral to specialist palliative care People with 
lung cancer were more often referred for PC or a 
consultation with a palliative medicine special‑
ist, with 81.7% of respondents always or often 
doing this. As to patients with COPD, only 18.3% 
of respondents (always or often) referred them 
for PC (TABLE 4).
Participants in end -of -life communication More 
than half of the respondents (often or always) 
discussed the EOL issues with the caregivers or 
the patient’s family only, with the patient being 
excluded from the conversation (54%; TABLE 6). On 
the other hand, only 8.6% of respondents always 
or often made the decisions regarding the EOL of 
patients with COPD along with other health care 
specialists without including patients or their 
caregivers or relatives.
Obstacles to end -of -life communication The fol‑
lowing key obstacles to initiating talks about 
the EOL issues with a patient who has end ‑stage 
COPD were identified: belief that a patient was 
not ready for such talk (68.4%); fear of strip‑
ping the patient of hope (64.9%); lack of the re‑
sources necessary to provide PC for the patient 
(49.4%); and certain inadequacies in training in 
this particular area (33.9%). More than 20% of 
respondents pointed to lack of clarity regarding 
the legal aspects of making medical decisions 
at the end of the patient’s life (23.6%) and to 
difficulties in predicting the actual progression 
of the disease (20.1%; FIGURE 1).
Similar obstacles were identified for people 
with lung cancer: fear of stripping hope (62.1%); 
belief that a patient was not ready for such dis‑
cussion (49.4%); inadequate training (28.2%); 
lack of the resources necessary to provide PC 
for the patient (21.3%); difficulties in predict‑
ing the actual progression rate of the disease 
(17.8%); and ignorance of pertinent legal as‑
pects (13.2%; FIGURE 1).
More respondents recognized obstacles ham‑
pering communication on EOL issues in people 
more physicians initiated such conversations 
with patients with lung cancer (always or of‑
ten, 39.1%).
With regards to patients with advanced COPD, 
the most frequently discussed topics were dis‑
ease progression (81% of respondents discussed 
it always or often) and everyday needs (always 
or often, 63.8%). Discussion on the EOL symp‑
toms were much less frequent (always or of‑
ten, 23.5%), similarly to talks on religious or 
spiritual needs (always or often, 16.1%; TABLE 4). 
The same topics were also most frequently ad‑
dressed in people with lung cancer. Mechani‑
cal ventilation was always or often discussed 
with people who had COPD by 35.6% of respon‑
dents. Patients with lung cancer were significant‑
ly less likely to have a discussion about mechan‑
ical ventilation (15%; TABLE 4). Only 12.6% of re‑
spondents discussed cardiopulmonary resusci‑
tation with patients with COPD, and 10.9% with 
patients with advanced lung cancer. Conversa‑
tions about the place of dying were rare in both 
patient populations. A higher number of peo‑
ple with COPD and lung cancer treated with‑
in a year positively influenced the initiation of 
EOL discussion by physicians (TABLE 5). A better 
knowledge of the PRS guidelines was related to 
more frequent initiation of a discussion on EOL 
issues with patients with COPD.
Pulmonologists who treated higher numbers 
of people with lung cancer were more inclined 
to initiate bedside discussions about the pre‑
ferred place of dying with both patient groups 
(TABLE 5). Younger physicians and those earlier in 
their careers were more open to discuss this top‑
ic with people who had lung cancer. Physicians 
who cared for a higher number of people with 
COPD were more inclined to suggest to a patient 
with COPD the need for making a decision re‑
garding invasive mechanical ventilation. Bet‑
ter knowledge of the guidelines was associated 
with more frequent initiation of discussion on 
the use of invasive ventilation and cardiopulmo‑
nary resuscitation with COPD patients (TABLE 5).
TABLE 4 End ‑of ‑life communication with people with advanced chronic obstructive pulmonary disease or advanced lung cancer (continued from the 
previous page)
Lung cancer COPD P value z score
Frequency of referring a patient 
for PC or to a palliative 
medicine specialist
1 – never 8 (4.6) 42 (24.1) <0.001 –11.41
2 – seldom 8 (4.6) 51 (29.3)
3 – occasionally 16 (9.2) 49 (28.2)
4 – often 81 (46.6) 26 (14.9)
5 – always 61 (35.1) 6 (3.4)
Median 4 2
Whether the discussions on EOL 
with an advanced COPD 
patient are needed and 
important for the patient
They are needed and important – 137 (78.7) – –
They are neither needed nor 
important
– 5 (2.9)
I have no opinion – 32 (18.4)
Data are presented as number (percentage) unless otherwise stated.
Abbreviations: EOL, end ‑of ‑life; others, see TABLES 1 and 2
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better sharing of information about the nature 
of their disease and encouraging their informed 
involvement in making pertinent therapeutic 
decisions (n = 15). Respondents also highlight‑
ed the importance of caring for patients’ fami‑
lies (n = 14), better access to psychological ser‑
vices (n = 13), and more empathy from attend‑
ing physicians (n = 8).
DISCUSSION Caring for people with advanced 
chronic obstructive pulmonary disease Despite 
Polish and other guidelines on COPD that 
recommend PC approach including efficient 
management of symptoms and advance care 
with COPD than lung cancer: the impression 
that patients are unprepared for facing such is‑
sues (68.4% and 49.4%, respectively) and lack of 
the resources necessary to provide PC for a pa‑
tient (49.4% and 21.3%, respectively).
Dignity in patients with chronic obstructive pulmonary 
disease Finally, an open question was posed on 
how to effectively enhance dignity in people with 
COPD approaching the end of life. We received 
108 answers, and the need for better access to PC 
centers or home PC was highlighted most often 
(n = 24). There were also numerous suggestions 
for more person ‑oriented treatment in terms of 
TABLE 5 Association between the variables and frequency of initiating discussions on end ‑of ‑life issues and of suggesting to a patient at an 
advanced stage of lung cancer and chronic obstructive pulmonary disease the need for making a decision regarding invasive mechanical ventilation, 
cardiopulmonary resuscitation, and a place of dying
Variable Test Frequency of initiating 
a talk on EOL issues
Frequency of suggesting to a patient at an advanced stage of 

















–0.10 –0.09 0.01 0.11 0.04 0.00 –0.20 –0.14
Significance NS NS NS NS NS NS <0.001 NS
Sexb Test value –1.47 –1.07 –0.64 –0.46 –0.44 –1.24 –0.36 –0.35
Significance NS NS NS NS NS NS NS NS
Work experiencea Correlation 
coefficient
–0.10 –0.10 0.04 0.10 0.02 0.00 –0.21 –0.14
Significance NS NS NS NS NS NS 0.001 NS
Number of COPD patients 
treated within a yeara
Correlation 
coefficient
0.18 0.18 0.13 0.25 0.08 0.10 0.12 0.11
Significance 0.006 0.007 NS <0.001 NS NS NS NS
Number of lung cancer 




0.18 0.24  – 0.04 0.10 0.05 0.13 0.20 0.19
Significance 0.005 <0.001 NS NS NS NS 0.003 0.005




–0.16 –0.21 –0.09 –0.25 0.07 –0.30 –0.10 –0.07
Significance NS 0.001 NS <0.001 NS <0.001 NS NS
Religious beliefs (believer or 
nonbeliever)b
Test value –1.87 –0.72 –0.06 –0.66 –0.50 –0.45 –1.00 –1.37
Significance NS NS NS NS NS NS NS NS
a The Kendall τ ‑b correlation coefficient was applied.
b The Mann–Whitney test was applied.
Abbreviations: see TABLES 1, 2, and 4
TABLE 6 Participants in end ‑of ‑life communication
1 – never 2 – seldom 3 – occasionally 4 – often 5 – always Median
Frequency of EOL discussions with the caregivers or 
relatives only, without the patient’s participation
7 (4) 27 (15.5) 46 (26.4) 71 (40.8) 23 (13.2) 4
Frequency of decisions on EOL issues regarding 
patients with end ‑stage COPD made by 
the respondent, along with other specialists, 
without including patients or their caregivers or 
relatives
47 (27) 64 (36.8) 48 (27.6) 14 (8) 1 (0.6) 2
Data are presented as number (percentage) unless otherwise stated.
Abbreviations: see TABLES 1 and 4
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chronic breathlessness, especially in COPD. Re‑
cently, we showed high incidence of opiophobia 
in Poland both among palliative care patients and 
physicians, creating an additional barrier to opti‑
mal treatment of chronic breathlessness.39,40 Half 
of Polish pulmonologists from the present study 
always or often prescribed antidepressant or anx‑
iolytic therapy in people with advanced COPD ex‑
periencing depression or anxiety disorders, simi‑
larly to Portuguese study (60%).18 Further work 
is required to understand why 50% of pulmon‑
ologists did not. 
Our survey revealed opportunities for better 
communication between pulmonologists and 
people with advanced COPD. Only 20% of re‑
spondents (always or often) initiated a discus‑
sion about EOL issues, which was comparable 
with results from a Portuguese study (13.2%).18 
Few clinicians initiated such conversations in‑
cluding the topic of advance care planning. Cli‑
nicians avoided bringing up end‑of‑life symp‑
toms, mechanical ventilation, or cardiopulmo‑
nary resuscitation. Respondents attributed bar‑
riers in an effective EOL approach to their be‑
lief that the patients were unprepared for facing 
such issues or that they did not want to destroy 
patients’ hopes. 
A perceived lack of resources for providing PC 
for patients with COPD was also reported. A re‑
cent systematic review of studies on the prac‑
tice of advance care planning among patients 
with chronic lung disease confirmed that it is un‑
common, possibly due to the complex course of 
planning,12-16,19,21-22 chronic breathlessness re‑
mains undertreated, physicians rarely initiate 
discussions on EOL issues and seldom refer their 
patients to a PC specialist.18,23-26 A total of 19% 
of respondents reported that they never pre‑
scribe opioids to people with chronic breath‑
lessness and COPD, which is similar to the re‑
sults from a study among Dutch chest physi‑
cians.24 Although the beneficial effects of opi‑
oids27-32 and their general safety (assuming that 
small, regular doses are prescribed) in relieving 
chronic breathlessness have been confirmed in 
various clinical trials,33-35 a significant percent‑
age of the respondents still express serious re‑
luctance to use them in practice. A similar atti‑
tude of pulmonologists was observed in a Por‑
tuguese study by Gaspar et al,18 in which 30% 
of respondents never or seldom used opioids in 
chronic breathlessness in patients with COPD. 
In our survey, 1 in 4 participants always or of‑
ten expressed concerns regarding opioids that 
make them reluctant to use those drugs in people 
with COPD and chronic breathlessness, which is 
consistent with other studies reporting that 15% 
to 56% of physicians were afraid of respiratory 
depression as an adverse effect of opioids in pa‑
tients with COPD.24,36-38 A recent meta ‑analysis 
showed no evidence of significant respiratory de‑
pression due to opioids used regularly at low dos‑
es for chronic breathlessness.35 Besides the lack of 
knowledge among physicians on when and how 
to use opioids, also preexisting fears contribute 
to doctors’ reluctance to prescribe opioids for 
FIGURE 1 Answers to a question on obstacles to communication about the end ‑of ‑life issues with regard to patients 
with end ‑stage chronic obstructive pulmonary disease (COPD) and lung cancer (multiple responses possible). 1 – 
impression that the patient is unprepared for facing such issues; 2 – fear of taking away all hope from a patient; 3 – 
deficits in professional training in this area; 4 – no resources to facilitate end ‑of ‑life or palliative care for a patient; 5 – 
difficulty in predicting progression of the disease; 6 – no command (or unclear view) of attendant legal aspects of 
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COPD patients apart from a few pilot programs 
such as the Integrated Care Model developed in 
Gdańsk, Poland.46,47
Better end -of -life care for patients with lung cancer 
than for those with chronic obstructive pulmonary 
disease When compared with patients with ad‑
vanced lung cancer, patients with advanced COPD 
are prescribed fewer opioids for the relief of mod‑
erate or severe pain and chronic breathlessness, 
and pulmonologists less often initiate bedside 
discussion on the EOL issues, refer them to PC, 
or ask PC specialist for consultation (TABLE 7). Con‑
cerns regarding the use of opioids, as expressed 
by physicians, were also more often related to pa‑
tients with COPD, but such fears do not reflect 
the available evidence. Further, pulmonologists 
more often talk about EOL symptoms and initiate 
a discussion on the place of dying with patients 
with advanced lung cancer. Discussions about in‑
vasive mechanical ventilation and cardiopulmo‑
nary resuscitation are more frequent in people 
with advanced COPD, but even then are initiat‑
ed only by a minority of physicians. Significant‑
ly more respondents recognized obstacles ham‑
pering communication on EOL issues in patients 
with COPD than with lung cancer, especially be‑
cause of concerns that patients are unprepared 
for facing such issues and lack of the resources 
required to provide PC. Respondents highlighted 
the need to facilitate better access to PC centers 
and recognition of the patient’s rights to honest, 
factual information about their medical condition.
Why are people with COPD referred for PC less 
often? A recent population ‑based survey from 
Belgium by Scheerens et al48 showed that treat‑
ment goals in the last week of life were less often 
aimed at comfort or palliation for COPD (59.1%) 
than for lung cancer (92.1%), and the use of any 
type of PC service was less common in COPD than 
in lung cancer (37.3% and 73.5%, respectively; 
P <0.001). In addition, the timing of referral was 
very close to death: a median of 6 days for COPD 
and 16 days for lung cancer. There is a need to de‑
fine the indications for referral of patients with 
COPD for PC based on the level and complexity 
of needs and to demonstrate the benefits of ear‑
ly integration of PC into their care.49
Who should the doctor talk to about end -of-life is-
sues? More than half of the respondents (of‑
ten or always) discussed EOL issues only with 
the caregivers or the patient’s family, with the pa‑
tient being excluded from the conversation (54%). 
It is one of the most surprising results of this sur‑
vey. In the Portuguese study,18 only 8.1% of re‑
spondents (often or always) had such conversa‑
tions without the patient. Further studies should 
clarify whether respondents understood correct‑
ly that they were being asked about situations 
in which patients were still able to make their 
own decisions. If yes, then such physicians’ at‑
titude to discuss EOL issues with the family or 
the disease and ambivalence of both patients and 
clinicians about engaging in these processes.41
Interestingly, in a recent multinational survey, 
nearly all pulmonologists and PC specialists from 
Australia, New Zealand, and United Kingdom par‑
ticipating in the study reported that they would 
initiate a discussion with the person described 
in a case vignette regarding prognosis and ad‑
vance care planning.42 While physicians of both 
specialties pointed at similar topics that need to 
be covered in advance care planning, palliative 
medicine physicians were more likely to discuss 
death and dying issues, prognosis, treatment lim‑
itations, and the place of future care. Researchers 
proposed the complementarity of a pulmonolo‑
gist and PC specialist, in which the former should 
initiate these discussions and the latter then de‑
velop and expand the conversations according 
to each patient’s needs and wishes, as the illness 
progresses.42 The cooperation between respira‑
tory medicine and PC has been recommended by 
international guidelines, which pointed at ear‑
ly implementation of the PC approach in paral‑
lel with disease ‑directed therapy.15,19 The ideal 
model should be based on good cooperation be‑
tween the pulmonologist and PC specialist as well 
as an easy access to PC care for COPD patients. 
There is also a steadily growing body of evidence 
for the benefits offered by PC, even in the early 
stages of the disease.43 However, in the majori‑
ty of countries referral to PC specialist services 
is still rare.44,45 In the United States, only 1.7% of 
patients with end ‑stage COPD who were depen‑
dent on home oxygen were referred to a PC spe‑
cialist when admitted with an exacerbation.45 In 
Poland there are no legal restrictions on access 
to PC by patients with advanced COPD. How‑
ever, there are no models of care for advanced 
TABLE 7 Communication on end ‑of ‑life issues and symptom management provided 
by pulmonologists for patients with advanced chronic obstructive pulmonary disease 
and advanced lung cancer
Selected aspects of treatment and 
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Data are presented as number (percentage).
Abbreviations: see TABLES 1, 2, and 4
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Conclusions The results of this study highlight 
a great need to improve the procedures for reliev‑
ing the symptoms and communicating more effec‑
tively with patients with advanced lung diseases. 
Palliative care standards for these patient groups 
should be more widely promoted, and a more com‑
passionate, whole ‑person care should be devel‑
oped.50 Models of integrated care including part‑
nership between pulmonologists and PC clini‑
cians should especially address the unmet needs 
of patients with advanced COPD. It is of particu‑
lar interest to find out whether the results of this 
survey are typical of Polish pulmonary physicians 
only, or perhaps indicative of a more universal 
phenomenon, so it would seem prudent to initi‑
ate a pan ‑European research project in this area.
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